| 1. Heinke R, Carlino L, Kannan S, Jung M, Sippl W.. (2011) Computer- and structure-based lead design for epigenetic targets., 19 (12): [PMID:21316248] [10.1016/j.bmc.2011.01.029] |
| 2. Jones P. (2012) Development of second generation epigenetic agents, 3 (2): [10.1039/C1MD00199J] |
| 3. Simon RP, Robaa D, Alhalabi Z, Sippl W, Jung M.. (2016) KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases., 59 (4): [PMID:26701186] [10.1021/acs.jmedchem.5b01502] |
| 4. Shrimp JH, Sorum AW, Garlick JM, Guasch L, Nicklaus MC, Meier JL.. (2016) Characterizing the Covalent Targets of a Small Molecule Inhibitor of the Lysine Acetyltransferase P300., 7 (2): [PMID:26985290] [10.1021/acsmedchemlett.5b00385] |
| 5. Yang Y, Zhang R, Li Z, Mei L, Wan S, Ding H, Chen Z, Xing J, Feng H, Han J, Jiang H, Zheng M, Luo C, Zhou B.. (2020) Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors., 63 (3): [PMID:31910017] [10.1021/acs.jmedchem.9b01721] |
| 6. Bouchut A, Rotili D, Pierrot C, Valente S, Lafitte S, Schultz J, Hoglund U, Mazzone R, Lucidi A, Fabrizi G, Pechalrieu D, Arimondo PB, Skinner-Adams TS, Chua MJ, Andrews KT, Mai A, Khalife J.. (2019) Identification of novel quinazoline derivatives as potent antiplasmodial agents., 161 [PMID:30366254] [10.1016/j.ejmech.2018.10.041] |
| 7. Wu F, Hua Y, Kaochar S, Nie S, Lin YL, Yao Y, Wu J, Wu X, Fu X, Schiff R, Davis CM, Robertson M, Ehli EA, Coarfa C, Mitsiades N, Song Y.. (2020) Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP., 63 (9): [PMID:32314924] [10.1021/acs.jmedchem.9b02164] |
| 8. Liu R, Zhang Z, Yang H, Zhou K, Geng M, Zhou W, Zhang M, Huang X, Li Y.. (2019) Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors., 180 [PMID:31306905] [10.1016/j.ejmech.2019.07.026] |
| 9. He ZX,Wei BF,Zhang X,Gong YP,Ma LY,Zhao W. (2021) Current development of CBP/p300 inhibitors in the last decade., 209 [PMID:33045661] [10.1016/j.ejmech.2020.112861] |
| 10. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius. (2021) HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators, [10.6019/CHEMBL4808148] |
| 11. Kanada R, Suzuki T, Murata T, Miyazaki M, Shimada T, Kuroha M, Minami M, Higuchi S, Tominaga Y, Naito H.. (2021) 4-Pyridone-3-carboxylic acid as a benzoic acid bioisostere: Design, synthesis, and evaluation of EP300/CBP histone acetyltransferase inhibitors., 51 [PMID:34534674] [10.1016/j.bmcl.2021.128358] |
| 12. Nie S, Wu F, Wu J, Li X, Zhou C, Yao Y, Song Y.. (2022) Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP., 237 [PMID:35512565] [10.1016/j.ejmech.2022.114407] |
| 13. Wang L, Bharti, Kumar R, Pavlov PF, Winblad B.. (2021) Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance., 209 [PMID:33139110] [10.1016/j.ejmech.2020.112915] |
| 14. Kanada R, Kagoshima Y, Asano M, Suzuki T, Murata T, Haruta M, Takahashi M, Ubukata O, Hashimoto K, Obata K, Kihara K, Kuroha M, Banjo T, Togashi N, Sato K, Yamamoto Y, Suzuki K, Isoyama T, Tominaga Y, Higuchi S, Naito H.. (2022) Discovery of EP300/CBP histone acetyltransferase inhibitors through scaffold hopping of 1,4-oxazepane ring., 66 [PMID:35413416] [10.1016/j.bmcl.2022.128726] |
